Literature DB >> 15703409

Transgenic expression of human connexin32 in myelinating Schwann cells prevents demyelination in connexin32-null mice.

Steven S Scherer1, Yi-Tian Xu, Albee Messing, Klaus Willecke, Kenneth H Fischbeck, Linda Jo Bone Jeng.   

Abstract

Mutations in Gap Junction beta1 (GJB1), the gene encoding the gap junction protein connexin32 (Cx32), cause the X-linked form of Charcot-Marie-Tooth disease (CMT1X), an inherited demyelinating neuropathy. We investigated the possibility that the expression of mutant Cx32 in other cells besides myelinating Schwann cells contributes to the development of demyelination. Human Cx32 was expressed in transgenic mice using a rat myelin protein zero (Mpz) promoter, which is exclusively expressed by myelinating Schwann cells. Male mice expressing the human transgene were crossed with female Gjb1/cx32-null mice; the resulting male offspring were all cx32-null (on the X chromosome), and one-half were transgene positive. In these transgenic mice, all of the Cx32 was derived from the expression of the transgene and was found in the sciatic nerve but not in the spinal cord or the liver. Furthermore, the Cx32 protein was properly localized (within incisures and paranodes) in myelinating Schwann cells. Finally, the expression of human Cx32 protein "rescued" the phenotype of cx32-null mice, because the transgenic mice have significantly fewer demyelinated or remyelinated axons than their nontransgenic littermates. These results indicate that the loss of Schwann-cell-autonomous expression of Cx32 is sufficient to account for demyelination in CMT1X.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15703409      PMCID: PMC6725992          DOI: 10.1523/JNEUROSCI.3082-04.2005

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

1.  GJB1/Connexin 32 whole gene deletions in patients with X-linked Charcot-Marie-Tooth disease.

Authors:  Claudia Gonzaga-Jauregui; Feng Zhang; Charles F Towne; Sat Dev Batish; James R Lupski
Journal:  Neurogenetics       Date:  2010-06-09       Impact factor: 2.660

2.  The role of gap junctions in Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa
Journal:  J Neurosci       Date:  2011-12-07       Impact factor: 6.167

3.  Mutations in ATP1A1 Cause Dominant Charcot-Marie-Tooth Type 2.

Authors:  Petra Lassuthova; Adriana P Rebelo; Gianina Ravenscroft; Phillipa J Lamont; Mark R Davis; Fiore Manganelli; Shawna M Feely; Chelsea Bacon; Dana Šafka Brožková; Jana Haberlova; Radim Mazanec; Feifei Tao; Cima Saghira; Lisa Abreu; Steve Courel; Eric Powell; Elena Buglo; Dana M Bis; Megan F Baxter; Royston W Ong; Lorna Marns; Yi-Chung Lee; Yunhong Bai; Daniel G Isom; René Barro-Soria; Ki W Chung; Steven S Scherer; H Peter Larsson; Nigel G Laing; Byung-Ok Choi; Pavel Seeman; Michael E Shy; Lucio Santoro; Stephan Zuchner
Journal:  Am J Hum Genet       Date:  2018-03-01       Impact factor: 11.025

Review 4.  Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.

Authors:  Axel Niemann; Philipp Berger; Ueli Suter
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 5.  Intermediate forms of Charcot-Marie-Tooth neuropathy: a review.

Authors:  Garth Nicholson; Simon Myers
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 6.  Molecular genetics of X-linked Charcot-Marie-Tooth disease.

Authors:  Kleopas A Kleopa; Steven S Scherer
Journal:  Neuromolecular Med       Date:  2006       Impact factor: 3.843

Review 7.  X-linked Charcot-Marie-Tooth disease.

Authors:  Steven S Scherer; Kleopas A Kleopa
Journal:  J Peripher Nerv Syst       Date:  2012-12       Impact factor: 3.494

8.  Characterization of the structure and intermolecular interactions between the connexin 32 carboxyl-terminal domain and the protein partners synapse-associated protein 97 and calmodulin.

Authors:  Kelly Stauch; Fabien Kieken; Paul Sorgen
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

9.  Intrathecal gene therapy rescues a model of demyelinating peripheral neuropathy.

Authors:  Alexia Kagiava; Irene Sargiannidou; George Theophilidis; Christos Karaiskos; Jan Richter; Stavros Bashiardes; Natasa Schiza; Marianna Nearchou; Christina Christodoulou; Steven S Scherer; Kleopas A Kleopa
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-28       Impact factor: 11.205

10.  Connexin32 mutations cause loss of function in Schwann cells and oligodendrocytes leading to PNS and CNS myelination defects.

Authors:  Irene Sargiannidou; Natalie Vavlitou; Sophia Aristodemou; Andreas Hadjisavvas; Kyriacos Kyriacou; Steven S Scherer; Kleopas A Kleopa
Journal:  J Neurosci       Date:  2009-04-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.